Annexon (ANNX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting commenced with a welcome from the CEO, highlighting the agenda and forward-looking statements subject to risk factors disclosed in SEC filings.
Procedures for orderly conduct and voting were outlined, with materials and agenda made available to participants.
Financial performance review
Cash runway extends into the second half of 2027, supporting key milestones including regulatory approvals and pivotal data readouts.
Board and executive committee updates
Board members and executive leadership were introduced, with acknowledgment of Tom Wiggans' retirement after eight years of service.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Annexon
- Q4 catalysts advance two late-stage programs, backed by runway into 2028.ANNX
Q3 2026 - ARCHER II tests vonaprument vision protection, with its month 15 analysis targeted for Q4 2026.ANNXStudy update
- GBS and GA catalysts in 2026 anchor a late-stage complement pipeline.ANNXInvestor presentation
- Phase III data show strong vision preservation in GA and rapid recovery in GBS, supporting global filings.ANNX12th Annual Cantor Fitzgerald Global Healthcare Conference
- Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation.ANNXWells Fargo 21st Annual Healthcare Conference
- Expanded trials, strong clinical results, and financing extend runway into 2028.ANNXQ2 2026
- Landmark GBS and GA programs advance toward regulatory milestones, with oral C1s poised for year-end data.ANNXWells Fargo 20th Annual Healthcare Conference 2025
- Phase III data for a novel vision-preserving therapy in GA expected Q4 2026, with strong pipeline progress.ANNXGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Three major clinical data readouts expected in 2024, each with strong differentiation.ANNXJefferies Global Healthcare Conference 2026